Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to market analysis. This trend is highlighted through responses to a survey taken from GlobalData’s State of the Biopharmaceutical Industry report, which reveals that industry professionals rate the impact of P&R processes among the top five leading factors currently impacting the sector. GlobalData is the parent company of Pharmaceutical Technology. In the survey, ...

Industry Overview - Copper prices declined in thin trading on the London Metal Exchange, influenced by rising stockpiles and a selloff in US technology stocks [1] - Futures in London fell as much as 2.1%, dipping below $12,600 a ton, with global inventories reaching the highest level since March [2] - Industrial demand for metals like copper has cooled in China, the world's largest consumer, due to near-record prices [3] Market Dynamics - The LMEX Index, which tracks six main base metals, hit a record last month due to Chinese buying and a weaker US dollar, but has since retreated as traders await new catalysts [4] - BHP Group reported a more than 20% increase in first-half earnings, with copper now accounting for over half of the company's profits, despite weaknesses in its China-focused iron ore and steel-making coal businesses [5] - Antofagasta Plc also reported record core earnings, but its shares fell due to declining copper and gold prices impacting mining stocks [5] Current Trading Conditions - As of 4:38 p.m. in London, copper futures were 1.5% lower at $12,657 a ton, with nickel down 1.4% and lead also declining [6]

Gold (GC=F) retreated more than 2% on Tuesday amid a broader market sell-off, but the recent volatility may be temporary as Wall Street analysts see the precious metal reaching new highs in 2026. Gold futures hovered around $4,900 as Asian markets closed for the Chinese New Year. Meanwhile, Iran and the US reached a “general agreement” on a possible nuclear deal, easing tensions in the Middle East. "Despite short-term softness, the structural drivers supporting gold remain firmly in place," Ole Hansen, ...

General Mills shares slide on slashed 2026 guidance Proactive uses images sourced from Shutterstock General Mills Inc (NYSE:GIS, XETRA:GRM) shares fell more than 7% on Tuesday after the consumer packaged goods company downwardly revised its 2026 outlook, citing weaker-than-expected consumer demand and heightened market uncertainty. The maker of Cheerios, Yoplait, and other major brands now expects organic net sales to decline 1.5% to 2% for the full year, compared with its prior forecast of a 1% decline t ...

Company Overview - Littelfuse, Inc. is a global provider of circuit protection and power management solutions, serving various end markets including industrial, automotive, and electronics [6] - The company was founded in 1927 and leverages a diversified product portfolio and global distribution network to support OEMs and industrial clients [6] - As of February 13, 2026, Littelfuse shares were priced at $359.55, with a market capitalization of $8.95 billion [4] Financial Performance - Littelfuse reported a total revenue of $2.39 billion for the trailing twelve months (TTM) [4] - The company experienced a net income loss of $71.70 million for the TTM [4] - The stock price has increased by 47.0% over the past year, outperforming the S&P 500 by 35.2 percentage points [3] Recent Transactions - Segall Bryant & Hamill, LLC sold 20,392 shares of Littelfuse in the fourth quarter, with an estimated transaction value of approximately $5.19 million [2] - Following the sale, Segall Bryant & Hamill's quarter-end position in Littelfuse was valued at $70.81 million, a decrease of $6.99 million from the previous quarter [2][3] - Littelfuse now represents 0.96% of Segall Bryant & Hamill's 13F reportable assets under management as of December 31, 2025 [3]

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the company received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its treatment. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and ...

ConocoPhillips (NYSE: COP) stock slipped 2.2% through 11:15 a.m. ET Tuesday on a double dose of "bad" news. First and most obviously, oil prices are down today, and for a company that makes its money selling oil, that's self-evidently bad news. Second, and less obviously, Roth/MKM just downgraded ConocoPhillips stock. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Image source: Getty ...

It would be easy to assume it was something within Kyndryl's (NYSE: KD) third-quarter numbers posted on Tuesday that's catapulting its stock. But, that's not quite it. Rather, KD stock is up 10.3% as of 11:31 a.m. ET today mostly because the technology company confirmed that corrections to a handful of quarterly results filed with the SEC in 2025 wouldn't need to be made. Investors are simply celebrating that Kyndryl is doing exactly as well as they were first led to believe it was doing all of last year. ...

Core View - CoreWeave (NASDAQ: CRWV) is positioned as a key player in the artificial intelligence infrastructure sector, benefiting from strong demand for GPU compute and long-term contracts with major AI companies [1] Group 1: Strategic Risks - The primary strategic risk for CoreWeave is that hyperscalers like AWS, Azure, and Google Cloud may become "good enough" in terms of performance, potentially diminishing CoreWeave's competitive edge [3] - CoreWeave currently enjoys a specialization advantage with infrastructure tailored for high-performance AI workloads, allowing it to outpace generalist cloud providers. However, hyperscalers are continuously investing in GPUs and AI-specific technologies, which could erode this advantage over time [4] - As GPU supply normalizes, enterprises may prioritize convenience and consolidation over performance, leading to potential pricing pressure and a shift back to existing cloud platforms, even if CoreWeave maintains a technical edge [5][6] Group 2: Capital Intensity - CoreWeave's significant capital expenditures are necessary for building AI infrastructure at scale, which requires substantial upfront investments in GPUs, power, cooling, and data centers. This capital intensity is currently a cost of entry into the market [7]

Agriculture adjusted EBIT margin was 6.5%, down from 7.2% in the prior-year quarter, as pricing and lower R&D partially offset negative product and regional mix and higher SG&A tied to variable compensation. On a full-year basis, CNH said gross tariff costs reduced Agriculture EBIT margin by 110 basis points, while unfavorable geographic and product mix reduced it by 90 basis points.In Agriculture, fourth-quarter net sales were about $3.6 billion, up 5% year-over-year, driven by favorable pricing and curren ...